Joel Lewis - Jan 24, 2022 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
President and CEO, Director
Signature
Jack W. Callicutt, by power of attorney
Stock symbol
GALT
Transactions as of
Jan 24, 2022
Transactions value $
$0
Form type
4
Date filed
1/25/2022, 03:15 PM
Previous filing
Jan 18, 2022
Next filing
Feb 1, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock Option (right to buy) Award $0 +70K $0.00 70K Jan 24, 2022 Common Stock 70K $1.98 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
F2 The options vest as follows: 25% on each of June 30, 2022; December 31, 2022; June 30, 2023; and December 31, 2023.